Fevipiprant-13CD3

Fevipiprant-13CD3 is a deuterated analogue of Fevipiprant, a selective and potent antagonist of the prostaglandin D2 receptor DP2 (also known as CRTH2). Fevipiprant-13CD3 is labeled with deuterium atoms, which are non-radioactive isotopes of hydrogen, and can be used in pharmacokinetic and pharmacodynamic studies to determine the metabolism, distribution, and elimination of the drug in vivo. Fevipiprant-13CD3 has been shown to be effective in the treatment of asthma and allergic rhinitis by inhibiting the activation of eosinophils, a type of white blood cell that plays a key role in the inflammatory response. The drug has also been investigated for the treatment of other inflammatory diseases including chronic obstructive pulmonary disease (COPD), atopic dermatitis, and nasal polyps. The chemical formula of Fevipiprant-13CD3 is C19H16D3F3N2O4S, with a molecular weight of 414.49 g/mol. It is a white or off-white powder that is soluble in dimethyl sulfoxide (DMSO) and ethanol. The drug has a half-life of approximately 10 hours and is primarily metabolized by the liver. In summary, Fevipiprant-13CD3 is a deuterated analogue of Fevipiprant that can be used in pharmacokinetic and pharmacodynamic studies to investigate the metabolism, distribution, and elimination of the drug in vivo. The drug is a selective and potent antagonist of the prostaglandin D2 receptor DP2, and has shown promise in the treatment of asthma, allergic rhinitis, and other inflammatory diseases.